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Expression of connective tissue growth factor in human renal fibrosis.
Chronic renal failure may occur in etiologically diverse renal diseases and
can be caused by hemodynamic, immunologic and metabolic factors.
Initial damage may evoke irreversible scarring, which involves production
of a number of proinflammatory and fibrogenic cytokines, including
platelet-derived growth factor (PDGF) and transforming growth factor b
(TGF-b). Connective tissue growth factor (CTGF), a cytokine of the
family of growth regulators comprising cef10, cyr61, CTGF and nov, has
recently been described in association with scleroderma and other scarring
conditions. We investigated CTGF mRNA expression in 65 human renal
biopsy specimens of various renal diseases by in situ hybridization. In
control human kidney CTGF mRNA was mainly expressed in visceral
epithelial cells, parietal epithelial cells, and some interstitial cells. Con-
nective tissue growth factor was strongly up-regulated in the extracapillary
and severe mesangial proliferative lesions of crescentic glomerulonephri-
tis, IgA nephropathy, focal and segmental glomerulosclerosis and diabetic
nephropathy. An increase in the number of cells expressing CTGF mRNA
was observed at sites of chronic tubulointerstitial damage, which corre-
lated with the degree of damage. In the tubulointerstitial area the majority
of the CTGF mRNA positive cells coexpressed a-smooth muscle actin,
and were negative for macrophage markers. Our results indicate that
CTGF may be a common growth factor involved in renal fibrosis.
Fibrosis is the final common pathway for almost all forms of
renal disease that progress to end-stage renal failure including
immunologically mediated glomerulonephritis and tubulointersti-
tial nephritis, hemodynamic disorders, metabolic diseases, and
hereditary diseases [1]. Histologically, such scarring consists of
glomerulosclerosis, tubulointerstitial fibrosis, as well as vascular
hyalinosis and sclerosis. Whatever the primary disturbance, fur-
ther mediators are required to cause renal scarring characterized
by cell proliferation and accumulation of matrix constituents [2].
An important role in this process was shown for the cytokines
platelet-derived growth factor (PDGF) and transforming growth
factor-b (TGF-b), as indicated by in vivo modulation of the
activity of these cytokines [3]. Blocking of the activity of PDGF or
TGF-b was shown to prevent extracellular matrix expansion and
glomerulosclerosis [4–7].
Connective tissue growth factor (CTGF) is a cysteine-rich
member of a new family of growth regulators, which are com-
prised of cef 10, cyr 61, CTGF and nov [8–12]. Connective tissue
growth factor was originally cloned from human umbilical vein
endothelial cells (HUVEC) [8]. Subsequently, skin fibroblasts in
scleroderma lesions were found to overexpress CTGF [13]. By
using a differential cloning technique, a cDNA clone identical to
CTGF was isolated from a human atherosclerotic aorta cDNA
library [14], in which expression was found to be 50- to 100-fold
increased as compared to normal arteries [14]. Connective tissue
growth factor was shown to induce kidney fibroblast proliferation
and extracellular matrix synthesis [15]. Effects of TGF-b on
fibroblasts were found to be partially mediated by CTGF [16].
The present study proposes the possible involvement of CTGF
in renal fibrosis. As a first step in the elucidation of its possible
role in renal sclerosis, we investigated the expression of human
CTGF mRNA in human biopsy specimens of various renal
diseases by in situ hybridization.
METHODS
Human kidney specimens
Sixty-five specimens from control and diseased human kidneys
were studied. Kidney samples were obtained from patients under-
going diagnostic evaluation at the Academic Medical Center of
the University of Amsterdam. Control human kidney specimens
(N 5 5) were taken from normal portions of nephrectomy
specimens of patients who underwent surgery because of localized
renal tumors. Specimens from diseased kidneys were obtained by
percutaneous renal biopsy from the patients with various renal
diseases. The histologic diagnoses are listed in Table 1. These
included minimal change nephrotic syndrome (MCNS), IgA
nephropathy (IgAN), idiopathic membranous nephropathy (MN),
focal glomerulosclerosis (FGS), crescentic anti-neutrophil cyto-
plasmic antibody (ANCA)-associated glomerulonephritis, lupus
nephritis (LN), diabetic glomerulosclerosis (DM), membranopro-
liferative glomerulonephritis (MPGN), chronic rejection of trans-
planted kidneys, acute postinfectious glomerulonephritis, and
nephrosclerosis. The classification of LN was based on the WHO
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histomorphological classification [17]. For light microscopy, kid-
ney tissues were fixed in 4% buffered formalin overnight, dehy-
drated and embedded in paraffin by conventional techniques.
Sections were stained with hematoxylin and eosin (HE), periodic
acid-Schiff (PAS), and silver methenamine (Jones).
In situ hybridization
The 1.5-kb EcoRI/KpnI fragment of CL59 cDNA of human
CTGF was used to produce antisense and sense probes [14].
Antisense and sense cRNA riboprobes were generated after
digestion with restriction enzymes EcoRI and XbaI. In vitro
transcription was performed using an RNA Labeling Kit (Boeh-
ringer-Mannheim, Germany). One microgram of linear template
DNA was used in each labeling reaction. The labeling reaction
components including transcription buffer, nucleotide-triphos-
phate (NTP) substrate, and T3 or T7 polymerase were mixed with
the linearized DNA. The mixture was incubated at 37°C for two
hours. During the transcription, digoxigenin-labeled uridine-
triphosphate (DIG-UTP) was incorporated into the transcription
products. The transcribed riboprobe was precipitated by 70%
ethanol, dissolved in 100 ml diethyl pyrocarbonate (DEPC; Sigma,
St Louis, MO, USA) treated water. The amount of DIG-labeled
RNA was measured with DIG quantification test strips and
control test strips (Boehringer-Mannheim). Four-micrometer se-
rial sections of formalin-fixed paraffin-embedded renal tissues
were placed on 3-aminopropyltriethoxysilane (Sigma) coated
slides. Sections were deparaffinized, treated with 0.2 M HCl for 20
minutes, digested with 10 mg/ml proteinase K for 20 minutes at
37°C, treated with 2 mg/ml glycine for two minutes and post-fixed
with 4% paraformaldehyde in PBS for 20 minutes. After treat-
ment with 10 mM EDTA the sections were subjected to hybrid-
ization. Digoxigenin (DIG)-labeled riboprobes (final concentra-
tion 0.3 mg/ml) were added to hybridization solution containing
50% deionized formamide, 10% dextran sulfate, 2 3 SSC, 2 3
Denhardt’s solution, 0.1% Triton X, 200 mg/ml Herring sperm
DNA (Boehringer-Mannheim), 100 mg/ml yeast transfer RNA
(Boehringer-Mannheim). Hybridizations were performed in a
humidified chamber for 18 hours at 52°C. The slides were washed
twice with 1 3 SSC containing 50% formamide at 52°C. After
washing with 1 3 SSC they were treated with 20 mg/ml RNAse A
for 30 minutes at 37°C. Washing was then continued with 1 3 SSC
twice and with 0.1 3 SSC once. After post-hybridization washing,
they were incubated with alkaline phosphatase-conjugated F(ab)
fragments of sheep anti-DIG antibody and then visualized with
nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-
phosphate, toluidine salt (NBT/BCIP) according to the DIG
nucleic acid detection kit protocol (Boehringer-Mannheim). The
sections were counterstained with hematoxylin or PAS without
hematoxylin. Slides were rinsed in distilled water and covered with
DAKO glycergel mounting medium (DAKO, Glostrup, Den-
mark).
Immunohistochemistry
Serial formalin-fixed paraffin sections were deparaffinized with
xylene, rehydrated, and washed with phosphate-buffered saline
(PBS). After blocking endogenous peroxidase activity with 0.3%
hydrogen peroxide and free protein binding sites with normal goat
serum, the tissue was incubated with primary murine monoclonal
antibodies, for a-smooth muscle actin (a-SMA, 1A4; DAKO) or
for CD68 (PG-M1; DAKO) during two hours at room tempera-
ture. Immunoreactivity for CD68 was enhanced by microwave
oven heating of sections in 10 mM sodium citrate, pH 6.0, for 10
minutes. Immobilized mouse antibodies were detected by the
immunoalkaline phosphatase anti-alkaline phosphatase method
with rabbit anti-mouse immunoglobulin (DAKO) and APAAP
complex (DAKO), or a streptavidin-biotin-immunoperoxidase
technique using the strept ABC complex/HRP kit (DAKO). The
specificity was checked by omission of primary antibodies and use
of non-immune mouse IgG as negative control.
Immunocytochemistry-in situ hybridization double labeling
In situ hybridization in combination with immunohistochemis-
try was performed on the same section to simultaneously detect
CD68 or a-SMA and CTGF mRNA. Sections were first hybrid-
ized with DIG-RNA probe and transcripts were detected. After
washing with PBS, endogenous biotin present in renal tissue was
blocked with 1 mg/ml streptavidin (Zymed, San Francisco, CA,
USA) and 0.1 mg/ml d-biotin (Sigma) in two successive steps.
Then tissues were stained with a-smooth muscle actin or CD68
monoclonal antibody. Microwave pretreatment enhanced the
reactivity for CD68. Presence of CTGF mRNA was visualized
with NBT/BCIP (purple-black) and a-SMA or CD68 were stained
with diaminobenzidine (brown). The results of the double staining
experiments showed staining patterns and staining intensities
similar to those obtained in simultaneously performed single
staining experiments.
Correlation between connective tissue growth factor mRNA
expression and tubulointerstitial injury
The correlation between interstitial CTGF expression and
chronic tubulointerstitial injury was assessed in 45 cases. Cases of
acute renal injury (6 cases of LN, and 7 cases of crescentic
ANCA-associated glomerulonephritis) were excluded. Another
seven cases were excluded because these lacked adequate tissue
for quantification of the interstitium. Tubulointerstitial expression
of the CTGF gene was determined by counting the CTGF mRNA
Table 1. Renal biopsy cases evaluated for connective tissue growth
factor (CTGF) mRNA expression
Diagnosis
No. of
cases
Normal 5
Minimal change disease 5
Focal and segmental glomerulosclerosis 6
Membranous nephropathy (non-lupus) Total 10
without glomerulosclerosis 7
with glomerulosclerosis 3
IgA nephropathy 11
Crescentic (ANCA-associated) GN 7
Chronic transplant rejection 6
Lupus nephritis Total 6
WHO class II 1
WHO class IV 3
WHO class V 2
Diabetic nephropathy 3
Acute GN (post-infectious) 2
Membranoproliferative GN 2
Nephrosclerosis 2
Total 65
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positive cells within the whole cortical area of each biopsy. At
least twenty fields of 0.044 mm2 were assessed and the average
number of positive cells in 0.1 mm2 was calculated. Tubulointer-
stitial injury was classified into four groups, according to the
extent of cortical interstitial fibrosis and of tubular atrophy and
degeneration: (1) normal; (2) involvement up to 25% of the
cortex; (3) involvement of 26 to 50% of cortex; and (4) extensive
damage involving more than 50% of the cortex. This is compara-
ble to the chronic change score in the Banff classification of
kidney transplant pathology [18].
Culture of glomerular visceral epithelial cells
For this study an established cell-line of glomerular visceral
epithelial cells (GVEC) was used, derived from Sprague-Dawley
rat glomeruli as has been described elsewhere [19–21]. This cell
line was found to express a ganglioside reported to be specific for
visceral and not parietal epithelial cells of the glomerulus [22].
The cell line was cultured and maintained in K1 medium contain-
ing hormone mix (all ingredients from Sigma), 100 U/ml penicillin
(Gibco, Gaithersburg, MD, USA), 100 mg/ml streptomycin
(Gibco) and 5% NuSerum (Collaborative Research Inc., Bedford,
MA, USA) on a collagen gel (Vitrogen 100; Collagen Corp, CA,
USA) in a humidified 5% CO2—95% air incubator, as described
[19]. Experiments were performed with GVEC at passage num-
bers 25 to 30.
RNA extraction and Northern blot analysis
Total RNA was isolated from renal cortical tissues of nephrec-
tomy specimens and from cultured GVEC by the TRIzol method
(Life Technologies, MD, USA).
Fifteen micrograms of total RNA were size separated by
electrophoresis on a 0.22 M formaldehyde-1% agarose gel, trans-
ferred to a nylon membrane, (Boehringer-Mannheim), and U.V.
cross-linked. Before transfer to a nylon membrane, ethidium-
stained gels were visualized by ultraviolet illumination to deter-
mine the position of 28S and 18S ribosomal RNA and to assess
the integrity of the RNA. Prehybridization and hybridization was
performed in DIG Easy Hyb (Boehringer-Mannheim), containing
yeast RNA or sheared heat-denatured herring sperm DNA.
Membranes were hybridized with a DIG-labeled CTGF cRNA
probe or with a 18S rRNA oligonucleotide probe [23], respec-
tively. The latter was used as a positive control and was labeled
using a DIG 39-End Labeling Kit (Boehringer-Mannheim). Fol-
lowing hybridization, the blots were washed twice with 2 3 SSC
containing 0.1% SDS at room temperature. Subsequently, the
blots were washed twice with 0.5 3 SSC, 0.1% SDS at 62°C for the
CTGF probe and at 42°C for the 18S rRNA oligonucleotide
probe. Hybridized probes were detected using alkaline phos-
phatase-conjugated F(ab) fragments of sheep anti-DIG anti-
body and the chemiluminescent substrate CSPD (Boehringer-
Mannheim), according to the manufacturer’s instructions.
Statistical analysis
All values are expressed as mean 6 SD. Statistical analysis was
performed with Statview IV software (Abacus Concepts, Berke-
ley, CA, USA). Statistical significance was evaluated by one way
analysis of variance with the modified t-test using Bonferroni
correction. The Spearman rank correlation coefficient was used
for analysis of correlation.
RESULTS
Connective tissue growth factor expression in control kidney
tissue
In the glomeruli of control human kidney, CTGF mRNA was
expressed mainly by visceral epithelial cells. CTGF transcripts
were also detected in some parietal epithelial cells (Fig. 1A).
Some interstitial cells in the peritubular and periglomerular areas
also showed CTGF expression (Fig. 1B). To determine the
cellular origin of the CTGF mRNA positive cells in the tubulo-
interstitial area, tissue sections were double-labeled for a-SMA
and CTGF mRNA and also for CD68 and CTGF mRNA. The
majority of the CTGF mRNA positive cells coexpressed a-SMA
and did not express CD68 antigen. CD68 positive cells also did not
coexpress CTGF mRNA (Fig. 1 C, D). These cells resemble
interstitial fibroblasts, but we could not completely exclude the
possibility that CTGF mRNA might be expressed in endothelial
cells of peritubular capillaries. All sections hybridized with a sense
probe were negative and binding of the antisense probes to these
cells was prevented by preincubation with RNAse.
Localization of connective tissue growth factor transcripts in
diseased kidney tissue
Connective tissue growth factor expression was found to be
normal as compared to control or only marginally increased in
glomerular diseases characterized by non-inflammatory lesions
and proteinuria, such as MCNS and MN, and in acute postinfec-
tious exsudative glomerulonephritis. In contrast, CTGF expres-
sion was found to be markedly increased in inflammatory glomer-
ular and tubulointerstital lesions, associated with cellular
proliferation and matrix accumulation. These lesions include IgA
nephropathy, chronic transplant rejection, crescentic glomerulo-
nephritis, FGS, lupus nephritis (WHO class IV) and MPGN.
Glomerular lesions. In three out of five MCNS and three out of
seven MN without glomerulosclerosis no up-regulation was ob-
served as compared to that in control renal tissue samples. In the
other two cases of MCNS and in the remaining four cases of MN
without glomerulosclerosis, CTGF mRNA expression was slightly
increased in visceral epithelial cells (Fig. 2). In disorders with
extracapillary proliferative lesions, a significant increase of CTGF
mRNA was noted in the glomeruli. In the cellular crescents of
crescentic glomerulonephritis, IgA nephropathy, and diffuse lu-
pus nephritis CTGF expression was strongly increased (Fig. 3 A,
B). According to immunostaining for CD68 and a-SMA, macro-
phages and myofibroblasts are not the main components of the
crescents (Fig. 3 C, D). This finding suggests that in these
crescents CTGF is mainly expressed by proliferating epithelial
cells. In the few remaining cells in fibrocellular crescents, CTGF
mRNA expression was still high. Connective tissue growth factor
expression was also increased in other extracapillary lesions,
including segmental sclerosis with adhesion to Bowman’s capsule
observed in FGS (Fig. 4) and MN with fibrosis. Although CTGF
expressing cells were mainly epithelial cells, severe mesangial
proliferative lesions in IgAN, diabetic diffuse lesions, and diffuse
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lupus nephritis also expressed CTGF (Fig. 5 A, B). In contrast,
CTGF was not up-regulated in postinfectious endocapillary pro-
liferative nephritis in spite of the numerous infiltrating neutro-
phils (Fig. 5 C, D).
Tubulointerstitial area. Uninjured portions of renal cortical
interstitial tissues were generally indistinguishable from the inter-
stitial patterns of sparse CTGF mRNA expression described
above in control kidneys. In the case of MCNS, FGS and MN
without interstitial fibrosis, CTGF mRNA positive cells were rare
in the tubulointerstitial area (Figs. 2 and 4). In contrast, increased
Fig. 1. Demonstration of connective tissue growth factor (CTGF) mRNA in control human kidney by in situ hybridization. CTGF mRNA is expressed
in visceral and parietal epithelial cells (A), and in some interstitial cells (B). Double-labeling is shown for a-SMA (brown) and CTGF mRNA
(purple-black) (C), and for CD68 (brown) and CTGF mRNA (purple-black) (D). In tubulointerstitial areas with slight fibrosis the majority of interstitial
CTGF mRNA positive cells coexpress a-smooth muscle actin (3250).
Fig. 2. In idiopathic membranous nephropathy, expression of connective
tissue growth factor (CTGF) mRNA is slightly increased in podocytes but
not present in the mesangial and tubulointerstitial area. This section was
counterstained with PAS without hematoxylin (3200).
Fig. 4. Renal biopsy from a patient with focal glomerularsclerosis (FGS).
PAS staining (A), and connective tissue growth factor (CTGF) mRNA
(B). CTGF expression is increased in segmental sclerotic lesions with
adhesion to Bowman’s capsule (3125).
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Fig. 3. Renal biopsy from a patient with crescentic glomerulonephritis. PAS staining (A), connective tissue growth factor (CTGF) mRNA (B), CD68
(C), and a-smooth muscle actin (D). In the cellular crescent, CTGF mRNA is mainly expressed by proliferated epithelial cells (3200).
Fig. 5. In situ hybridization for connective tissue growth factor (CTGF) mRNA reveals CTGF upregulation in severe mesangial proliferative lesions
of diabetes mellitus (DM) nephropathy diffuse lesion (A) and IgA nephropathy (B). In contrast, CTGF is not up-regulated in acute postinfectious
glomerulonephritis (C, PAS stain; D, CTGF; 3200).
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Fig. 6. Connective tissue growth factor (CTGF) expression in tubuloin-
terstitial fibrosis. Renal biopsy of a case showing a focal zone of tubular
atrophy and interstitial fibrosis (lower part of photograph), with adjacent
areas of well-preserved tubular architecture. (A, PAS stain) Serial sections
of the same biopsy show that CTGF mRNA is expressed strongly in the
zones of interstitial fibrosis as compared to its expression in normal
appearing adjacent tubular parenchyma (B). The distribution of CTGF is
similar to that of a-SMA staining (C) (380).
Fig. 7. Connective tissue growth factor (CTGF) expression in periglo-
merular fibrosis in a case of focal glomerulosclerosis (FGS) with hyper-
tension (A, PAS stain; B, CTGF mRNA; and C, a-smooth muscle actin
stain on serial sections). CTGF expression is increased in the periglo-
merular lesion and in lesions of proliferated visceral and parietal epithelial
cells. CTGF is expressed by a-smooth muscle actin positive cells in the
periglomerular interstitial fibrosis (3200).
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numbers of CTGF mRNA positive cells were identified within the
tubulointerstitial fibrotic areas in chronic transplant rejection, and
in the chronic interstitial damage in the context of glomerulone-
phritides. Within these lesions, the distribution of CTGF mRNA
positive cells was similar to that of a-SMA staining (Fig. 6). Also
in periglomerular fibrosis, CTGF mRNA was strongly up-regu-
lated in a-SMA positive cells (Fig. 7). A statistically highly
significant correlation between the extent of tubulointerstitial
fibrosis and the number of CTGF mRNA positive cells per surface
area was demonstrated (Fig. 8) using the Spearman rank corre-
lation coefficient (r 5 0.849; P , 0.001).
Vessels. In atherosclerotic arteries not only smooth muscle cells,
but also endothelial cells showed CTGF gene expression (not
shown).
Northern blot analysis
By Northern analysis, a 2.4 Kb CTGF transcript was detected in
RNA extracted from control human kidney (Fig. 9A) and from
cultured podocytes (Fig. 9B).
DISCUSSION
A widely accepted paradigm in concepts of development of
renal fibrosis is that TGF-b up-regulation is a main factor
responsible for fibrotic changes and scarring in response to renal
injury [3]. Its importance in glomerulosclerosis has been estab-
lished by in vivo studies and by analysis of glomerular cells in
culture [24–29]. Inhibition of overexpression of TGF-b by anti-
sense oligonucleotides [30] or decorin [6, 7] suppressed the
accumulation of extracellular matrix in experimental glomerulo-
nephritis induced by anti-Thy-1.1 antibody. Transforming growth
factor-b is a pleiotropic factor with many effects also not directly
related to fibrosis and scarring, including immunosuppressive and
anti-inflammatory activities [31]. Intervention by blocking TGF-b
may therefore have conflicting effects. Identification of a factor
downstream of TGF-b that is directly involved in the accumula-
tion of matrix might provide a better target for intervention.
Studies by Grotendorst and Oemar have demonstrated that
CTGF is a novel growth factor that can be up-regulated in
fibroblasts and vascular smooth muscle cells by TGF-b [14, 32,
33]. It is a chemoattractant and mitogen for fibroblasts [8] and it
also induces extracellular matrix deposition [15]. Connective
tissue growth factor significantly increased type I collagen and
fibronectin production, as well as expression of a5 integrin by a
normal kidney fibroblast cell line [15]. In vivo subcutaneous
injection of CTGF induced connective tissue cell proliferation and
matrix deposition [15]. Moreover, the induction of anchorage-
independent growth of fibroblasts by TGF-b appears to be
mediated by a CTGF-dependent pathway [16]. It thus appears
that CTGF may mediate at least part of the fibrosis inducing
activity of TGF-b.
In the present study, using DIG-labeled RNA in situ hybridiza-
tion on paraffin sections of human renal biopsies, we have
observed that a strong increase of CTGF mRNA expression is a
general phenomenon in proliferative and fibrotic renal lesions. In
the glomeruli of control human kidney samples taken from
nephrectomy specimens with renal cell carcinoma we detected
baseline expression of CTGF in visceral and parietal epithelial
cells. This is in agreement with detection of the 2.4 Kb CTGF
mRNA transcript by Northern analysis of control kidney tissue, as
well as of cultured podocytes which thus appear to express CTGF
under basal conditions.
In the glomerular lesions CTGF was not increased in postin-
fectious endocapillary GN, and also not or only slightly incresed in
MCNS and MN. In all other types of lesions characterized by
cellular proliferation, CTGF expression was found to be up-
regulated. The cell type expressing CTGF and the degree of
up-regulation varied with the type of lesion. Since TGF-b has
Fig. 8. Relationship between the number of interstitial connective tissue
growth factor (CTGF)-expressing cells and the extent of tubulointerstitial
lesions. Data are expressed as the mean 6 SD. *P , 0.0001, as compared
to the group without tubulointerstitial lesions, scored as 0%.
Fig. 9. Determination of connective tissue growth factor (CTGF) expres-
sion in control kidney tissue (A), and in podocytes under basal culture
conditions (B) by Northern blot analysis. Podocytes expressed a 2.4 Kb
transcript, consistent with the predictive size of CTGF. The position of
28S and 18S ribosomal RNA is indicated on the left.
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been documented to be increased in a variety of chronic forms of
renal injury and TGF-b was found to induce expression of CTGF
in various celltypes [14, 32, 33] including mesangial cells and
podocytes (Y. Ito, manuscript in preparation), CTGF may have a
role, downstream of TGF-b, in a final common pathway leading to
fibrosis in etiologically diverse diseases. In addition to TGF-b,
other stimuli may enhance CTGF expression. For instance, CTGF
mRNA expression was found to be increased in the absence of
TGF-b up-regulation in a monkey renal epithelial cell line, both
after exposure to calcium-oxalate-monohydrate crystals and after
scrape wounding of monolayers [34, 35].
With respect to the source of fibrogenic growth factors in the
kidney, macrophages and mesangial cells have thus far received
most attention. As far as CTGF is concerned, our results suggest
that leukocytes do not significantly express this growth factor.
Connective tissue growth factor expression in the mesangium was
up-regulated in mesangial proliferative lesions, mainly in diabetic
nephropathy and mesangial proliferative lesions in IgA nephrop-
athy, but less so than CTGF expression in the epithelial lesions of
other glomerulopathies. CTGF mRNA expression was strongly
increased in particular in extracapillary proliferative lesions, cap-
sular adhesions, and periglomerular fibrosis. Three different cell
types including interstitial fibroblasts, mesangial cells, and epithe-
lial cells have been shown to express CTGF mRNA. It should be
noted that these cells all share a mesodermal origin. Endothelial
CTGF expression in glomeruli was not prominent. However,
CTGF can be expressed by endothelium from other vessels, like
human umbilical vein [8] and atherosclerotic arteries [14].
Tubulointerstitial injury is an important parameter in the
assessment of renal damage because it correlates well with the
decline in renal function and long-term progression [36, 37]. Many
potentially fibrogenic factors, including TGF-b1, have been impli-
cated in tubulointerstitial injury [38–41]. Our present data show a
strong increase at the sites of chronic tubulointerstitial damage of
the number of cells expressing CTGF mRNA, which significantly
correlates with the degree of tubulointerstitial damage. In the
tubulointerstitial area, macrophages and fibroblasts are the most
important source of TGF-b1 [2]. Transforming growth factor-b
[42] and PDGF-B [43] were shown to induce transformation of
fibroblasts to myofibroblasts (a-smooth muscle actin positive
cells), which are major contributors to matrix deposition in the
tubulointerstitial area. The presence of myofibroblasts within the
renal interstitium correlates with the extent of tubulointerstitial
scarring and functional outcome in clinical [44, 45] and experi-
mental glomerulonephritis [46, 47]. In both control and patholog-
ical conditions, we observed that the majority of CTGF positive
cells in the tubulointerstitial area were myofibroblasts, as defined
by coexpression of a-smooth muscle actin, and not macrophages.
This suggests both autocrine and paracrine inductions of this
factor by TGF-b.
In summary, a local increase of CTGF expression may play a
role in the development and progression of glomerulosclerosis
and tubulointerstitial fibrosis. The relative importance of CTGF
in these different processes will have to be established by manip-
ulation of CTGF levels in the presence or absence of other
fibrogenic cytokines.
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APPENDIX
Abbreviations used in this article are: a-SMA, a-smooth muscle actin;
ANCA, anti-neutrophil cytoplasmic antibody; CTGF, connective tissue
growth factor; DEPC, diethyl pyrocarbonate; DIG-UTP, digoxigenin-
labeled uridine-triphosphate; DM, diabetes mellitus, FGS, focal glomer-
ulosclerosis; GVEC, glomerular visceral epithelial cells; HE, hematoxylin
and eoson stain; HUVEC, human umbilical vein endothelial cells; IgAN,
IgA nephropathy; LN, lupus nephritis; MCNS, minimal change nephrotic
syndrome; MN, idiopathic membranous nephropathy; NBT/BCIP, ni-
troblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl-phosphate;
NTP, nucleotide-triphosphate; PAS, periodic acid-Schiff stain; PBS, phos-
phate buffered saline; PDGF, platelet-derived growth factor; TGF-b,
transforming growth factor-b.
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